Literature DB >> 10532953

Diminished basal phosphorylation level of phospholamban in the postinfarction remodeled rat ventricle: role of beta-adrenergic pathway, G(i) protein, phosphodiesterase, and phosphatases.

B Huang1, S Wang, D Qin, M Boutjdir, N El-Sherif.   

Abstract

Three weeks after myocardial infarction (MI) in the rat, remodeled hypertrophy of noninfarcted myocardium is at its maximum and the heart is in a compensated stage with no evidence of heart failure. Our hemodynamic measurements at this stage showed a slight but insignificant decrease of +dP/dt but a significantly higher left ventricular end-diastolic pressure. To investigate the basis of the diastolic dysfunction, we explored possible defects in the beta-adrenergic receptor-G(s/i) protein-adenylyl cyclase-cAMP-protein kinase A-phosphatase pathway, as well as molecular or functional alterations of sarcoplasmic reticulum Ca(2+)-ATPase and phospholamban (PLB). We found no significant difference in both mRNA and protein levels of sarcoplasmic reticulum Ca(2+)-ATPase and PLB in post-MI left ventricle compared with control. However, the basal levels of both the protein kinase A-phosphorylated site (Ser16) of PLB (p16-PLB) and the calcium/calmodulin-dependent protein kinase-phosphorylated site (Thr17) of PLB (p17-PLB) were decreased by 76% and 51% in post-MI myocytes (P<0.05), respectively. No change was found in the beta-adrenoceptor density, G(salpha) protein level, or adenylyl cyclase activity. Inhibition of phosphodiesterase and G(i) protein by Ro-20-1724 and pertussis toxin, respectively, did not correct the decreased p16-PLB or p17-PLB levels. Stimulation of beta-adrenoceptor or adenylyl cyclase increased both p16-PLB and p17-PLB in post-MI myocytes to the same levels as in sham myocytes, suggesting that decreased p16-PLB and p17-PLB in post-MI myocytes is not due to a decrease in the generation of p16-PLB or p17-PLB. We found that type 1 phosphatase activity was increased by 32% (P<0.05) with no change in phosphatase 2A activity. Okadaic acid, a protein phosphatase inhibitor, significantly increased p16-PLB and p17-PLB levels in post-MI myocytes and partially corrected the prolonged relaxation of the [Ca(2+)](i) transient. In summary, prolonged relaxation of post-MI remodeled myocardium could be explained, in part, by altered basal levels of p16-PLB and p17-PLB caused by increased protein phosphatase 1 activity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10532953     DOI: 10.1161/01.res.85.9.848

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  27 in total

1.  Type 1 phosphatase, a negative regulator of cardiac function.

Authors:  Andrew N Carr; Albrecht G Schmidt; Yoichi Suzuki; Federica del Monte; Yoji Sato; Carita Lanner; Kristine Breeden; Shao-Ling Jing; Patrick B Allen; Paul Greengard; Atsuko Yatani; Brian D Hoit; Ingrid L Grupp; Roger J Hajjar; Anna A DePaoli-Roach; Evangelia G Kranias
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

2.  Protein phosphatases decrease sarcoplasmic reticulum calcium content by stimulating calcium release in cardiac myocytes.

Authors:  Dmitry Terentyev; Serge Viatchenko-Karpinski; Inna Gyorke; Radmila Terentyeva; Sandor Gyorke
Journal:  J Physiol       Date:  2003-08-01       Impact factor: 5.182

Review 3.  Altered intracellular Ca2+ handling in heart failure.

Authors:  Masafumi Yano; Yasuhiro Ikeda; Masunori Matsuzaki
Journal:  J Clin Invest       Date:  2005-03       Impact factor: 14.808

4.  Myocardial infarction causes increased expression but decreased activity of the myocardial Na+-Ca2+ exchanger in the rabbit.

Authors:  F R Quinn; S Currie; A M Duncan; S Miller; R Sayeed; S M Cobbe; G L Smith
Journal:  J Physiol       Date:  2003-08-29       Impact factor: 5.182

Review 5.  Ion Channels in the Heart.

Authors:  Daniel C Bartos; Eleonora Grandi; Crystal M Ripplinger
Journal:  Compr Physiol       Date:  2015-07-01       Impact factor: 9.090

6.  Accurate quantitation of phospholamban phosphorylation by immunoblot.

Authors:  Naa-Adjeley Ablorh; Tyler Miller; Florentin Nitu; Simon J Gruber; Christine Karim; David D Thomas
Journal:  Anal Biochem       Date:  2012-02-03       Impact factor: 3.365

7.  Molecular mechanisms underlying cardiac protein phosphatase 2A regulation in heart.

Authors:  Sean T DeGrande; Sean C Little; Derek J Nixon; Patrick Wright; Jedidiah Snyder; Wen Dun; Nathaniel Murphy; Ahmet Kilic; Robert Higgins; Philip F Binkley; Penelope A Boyden; Cynthia A Carnes; Mark E Anderson; Thomas J Hund; Peter J Mohler
Journal:  J Biol Chem       Date:  2012-11-30       Impact factor: 5.157

Review 8.  Altered sarcoplasmic reticulum calcium cycling--targets for heart failure therapy.

Authors:  Changwon Kho; Ahyoung Lee; Roger J Hajjar
Journal:  Nat Rev Cardiol       Date:  2012-10-23       Impact factor: 32.419

Review 9.  Regulation of sarcoplasmic reticulum Ca2+ release by serine-threonine phosphatases in the heart.

Authors:  Dmitry Terentyev; Shanna Hamilton
Journal:  J Mol Cell Cardiol       Date:  2016-08-29       Impact factor: 5.000

Review 10.  Regulating the regulator: Insights into the cardiac protein phosphatase 1 interactome.

Authors:  David Y Chiang; Albert J R Heck; Dobromir Dobrev; Xander H T Wehrens
Journal:  J Mol Cell Cardiol       Date:  2016-09-20       Impact factor: 5.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.